drugset / Trial / NCT00126789

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

NCT00126789

Phase 3 Terminated 24 enrolled ZARS Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.

Timeline

Start
2005-08
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Other
Subject Fentanyl Other / unclassified 50 ug Other
Subject Fentanyl Other / unclassified 75 ug Other
Subject Fentanyl Other / unclassified 100 ug Other

Indications